Table 3.
Bliss coefficient for drug combination. The EC50 was determined for each compound in the combination experiment. For the letermovir combinations, a plaque reduction assay was performed with HCMV Towne. The GCV combinations used the pp28-luciferase HCMV Towne except for GCV and NCGC2995 which was performed with HCMV TB40. Letermovir combination assays were performed in a single experiment, whereas GCV combination with the specified compounds was performed in separate experiments for which the EC50 was determined.
| Compound 1 | EC50 | Compound 2 | EC50 (μM) | Bliss Coefficient |
|---|---|---|---|---|
| Letermovir | 1.1 ± 0.1 (nM) | MLS8969 | 0.32 ±0.0 | 1.2 |
| NFU1827 | 0.61 ±0.1 | 1.2 | ||
| MLS8554 | 0.14 ±0.0 | 1.0 | ||
| MLS8091 | 0.13 ±0.1 | 1.3 | ||
| NCGC2955 | 3.19 ±0.2 | 1.1 | ||
| GCV | 1.33 ± 0.2 (μM) | MLS8969 | 0.72 ±0.1 | 0.9 |
| GCV | 1.63 ±0.2 | NFU1827 | 0.69 ± 0.1 | 1.2 |
| GCV | 1.91 ±0.6 | MLS8554 | 0.55 ± 0.0 | 1.1 |
| GCV | 1.25 ±0.6 | MLS8091 | 0.57 ±0.1 | 1.3 |
| GCV | 0.77 ±0.1 | NCGC2955 | 1.51 ±0.0 | 0.9 |